Tech Company Financing Transactions
Tessera Therapeutics Funding Round
Tessera Therapeutics, based in Cambridge, received $300 million in investment from Abu Dhabi Investment Authority, Alaska Permanent Fund and Altitude Life Science Ventures.
Transaction Overview
Company Name
Announced On
4/19/2022
Transaction Type
Venture Equity
Amount
$300,000,000
Round
Series C
Investors
Proceeds Purpose
This latest funding round is a testament to the immense potential of this bioplatform to provide new treatments and cures to previously untreatable genetic diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
55 Cambridge Pkwy. 800E
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Geoffrey von Maltzahn
Chief Scientific Officer
Jacob Rubens
Vice President
Stephen Cleaver
Vice President
Cecilia Cotta-Ramusino
VP - Bus. Development
Vikram Ranade
Browse more venture capital transactions:
Prev: 4/19/2022: The Food Lab venture capital transaction
Next: 4/19/2022: Experify venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. All VC database entries on this site come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs